Salvador F. Gutierrez-Aguirre

Dr. Salvador F. Gutierrez-Aguirre

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2022 in Neurosurgical Review
Verified
Journal Article
Closed access
PDF file
PAPedro Aguilar-Salinas
Pedro Aguilar-Salinas
SGSalvador F. Gutierrez-Aguirre
Salvador F. Gutierrez-Aguirre
MAMauricio J. Avila
Mauricio J. Avila
PNPeter Nakaji
Peter Nakaji

10 May 2024 in World Neurosurgery
Verified
Journal Article
Closed access
OTOtavio F. De Toledo
Otavio F. De Toledo
SGSalvador F. Gutierrez-Aguirre
Salvador F. Gutierrez-Aguirre
MLMontserrat Lara-Velazquez
Montserrat Lara-Velazquez
AQAdnan I. Qureshi
Adnan I. Qureshi
WCWendy Camp
Wendy Camp
RHRicardo Hanel
Ricardo Hanel

7 November 2024 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
PDF file
RHRicardo A Hanel
Ricardo A Hanel
VJVinay Jaikumar
Vinay Jaikumar
SGSalvador F. Gutierrez-Aguirre
Salvador F. Gutierrez-Aguirre
HKHamid Sharif Khan
Hamid Sharif Khan
OTOtavio F De Toledo
Otavio F De Toledo
ASAdnan H Siddiqui
Adnan H Siddiqui
Background: Heavily calcified carotid stenosis (HCCS) is considered an exclusion for carotid angioplasty and/or stenting (CAS), amenable only to carotid endarterectomy. This study presents preliminary retrospective dual-center experience utilizing the Shockwave S 4 intravascular lithotripsy (IVL) system (Shockwave Medical) as an adjunct to CAS for HCCS. Methods: Patients with symptomatic or asymptomatic HCCS (de novo stenosis or in-stent restenosis (ISR)) undergoing IVL+CAS were included. Charts were reviewed for demographic, imaging, procedural, and outcome data. The primary endpoint was composite major adverse event (MAE) rate: death, ipsilateral stroke, or myocardial infarction (MI) within 30 days of IVL+CAS. Secondary endpoints included technical and procedural success, residual stenosis, and ISR postprocedure. Results: Fifteen patients underwent 17 IVL+CAS procedures: de novo HCCS=13, heavily calcified ISR=4; symptomatic disease was addressed in seven cases. Procedures were performed transfemorally under conscious sedation with dual protection; flow reversal through a balloon guide catheter, and distal embolic protection system (EPS) use. Median pre-IVL+CAS stenosis was 73% (IQR 60–80%). Technical success (IVL+CAS+ EPS use) was achieved in all cases. Median post-IVL+CAS residual stenosis was 27% (IQR 12–33%), achieving <50% residual stenosis and procedural success in all. Five patients required dopamine infusion for postprocedural hypotension. No periprocedural ipsilateral strokes occurred. MAE rate was 6.7% (95% CI 0.2% to 32%), including one MI resulting in death. Additionally, one ISR (6.3%; 95% CI 0.2% to 30.2%) identified 160 days after IVL+CAS was retreated with angioplasty. Conclusions: IVL+CAS was safe and effective for treating symptomatic and asymptomatic HCCS, achieving high rates of freedom from MAE. IVL has potential to expand the role of CAS in difficult to treat HCCS.

1 October 2024 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
PDF file
FRFernanda Rodriguez-Erazú
Fernanda Rodriguez-Erazú
GCGustavo M Cortez
Gustavo M Cortez
DLDemetrius K Lopes
Demetrius K Lopes
SGSalvador F. Gutierrez-Aguirre
Salvador F. Gutierrez-Aguirre
OTOtavio Frederico De Toledo
Otavio Frederico De Toledo
RHRicardo Hanel
Ricardo Hanel
Background The pipeline embolization device (PED) has been increasingly used to treat brain aneurysms; however, concerns have been raised about braid stability with newer drawn filled tubing technology devices. Objective To evaluate braid stability of PED early generations using data from the PREMIER trial. Methods All consecutive intracranial aneurysms treated with PED (Classic and Flex) within the PREMIER trial were reviewed for braid stability (fish mouthing, foreshortening, braid bump, braid collapsing). Immediate postprocedure cone-beam CT and angiography were compared with 1- and 2- years' follow-up. Analyses included safety, measured with the modified Rankin Scale (mRS) score, including +1 mRS point and a good clinical outcome (mRS score 0–2), vessel stenosis ≥50%, effectiveness measured with Raymond-Roy Scale, and re-treatment rates. Results 133/141 aneurysms had a complete dataset. 8/133 (6%) aneurysms showed braid deformations. Inter-reader agreement was excellent (κ=0.83). Braid deformations were statistically significantly associated with in-stent vessel stenosis >50% (P=0.029), without impact on effectiveness or safety. Fish mouthing was found in 1/133 (0.75%) at 1 year, causing >50% vessel stenosis. Foreshortening occurred in 6/133 (4.5%), and braid bump in 1/133 (0.75%) associated with severe in-stent stenosis. Four other cases (3.0%) of asymptomatic in-stent stenosis due to neointimal hyperplasia were seen without braid changes. No new braid stability deformations were found at the 2-year follow-up. Conclusion Our study demonstrates excellent braid stability among patients treated with the PED Classic and Flex in the PREMIER trial. Within the uncommon braid changes observed, none affected the PED safety or efficacy. Trial registration number NCT02186561.

2 June 2025 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
AAAmin Aghaebrahim
Amin Aghaebrahim
OTOtavio F De Toledo
Otavio F De Toledo
FEFernanda Erazú
Fernanda Erazú
SGSalvador F. Gutierrez-Aguirre
Salvador F. Gutierrez-Aguirre
BJbrian jankowitz
brian jankowitz
RHRicardo Hanel
Ricardo Hanel
Background and objectives: Large-bore aspiration catheters have demonstrated better recanalization times and higher first-pass effects in large vessel occlusions. However, vessel tortuosity and branching vessels can hinder navigability, potentially increasing the ‘ledge effect’, procedural times, and the risk of vessel injury. Recently, a newly designed delivery catheter (Carrier Delivery Catheter (CDC), Balt, France) has been introduced to the US market. This paper aims to report our combined experience with this catheter in a real-life clinical setting. Methods: This is a retrospective, multicenter study based on a prospectively maintained database of patients with ischemic stroke who underwent mechanical thrombectomy between February 2024 and January 2025. All consecutive patients who underwent mechanical thrombectomy in which a CDC was used were included. Results: A total of 43 patients from three centers in the USA were included. The mean age was 69.74 years, and most of the patients were male (60.5%). The CDC delivered the aspiration catheter to the clot in all cases. The mean National Institutes of Health Stroke Scale (NIHSS) score was 18, and the mean time between puncture to clot access was 18.14 min. No vessel dissection or perforation was reported, and 4.6% of symptomatic hemorrhagic complications were reported. None of the complications were adjudicated to be directly related to the use of the Carrier. Conclusion: Our case series shows that the CDC is a useful and reliable tool as a delivery catheter for treating vessel occlusions in both the anterior and posterior circulation. This study serves as proof of concept and may provide a foundation for future prospective analyses of this innovative delivery system.

8 February 2024 in Operative Neurosurgery
Verified
Journal Article
Closed access
OTOtavio F. De Toledo
Otavio F. De Toledo
SGSalvador F. Gutierrez-Aguirre
Salvador F. Gutierrez-Aguirre
VBVictor H. C. Benalia
Victor H. C. Benalia
MLMontserrat Lara-Velazquez
Montserrat Lara-Velazquez
AAAmin Aghaebrahim
Amin Aghaebrahim
RHRicardo Hanel
Ricardo Hanel
Y/stent, and transcervical carotid revascularization, certain patients are not ideal candidates for any of these modalities. Novel technical advances such as intravascular lithotripsy (Shockwave Medical Inc.) have emerged as a potential treatment modality to treat patients with severely calcified plaques, a well-described limitation for carotid stent expansion and apposition.2-4 The safety and efficacy of intravascular lithotripsy have been demonstrated through select case series and coronary artery disease I‐II‐III studies, culminating in its Food and Drug Administration approval for the management of novo, calcified, stenotic coronary arteries before stent placement.2,5 This technical video presents an illustrative case of a patient with symptomatic severely calcified carotid plaque with previous neck radiation precluding endarterectomy, treated with off-label use of balloon lithotripsy plus stent.6 The patient consented to the procedure....